BACKGROUND INFORMATION ON THE PROCEDURE 
1.1  Submission of the dossier 
The  applicant  Schwarz  Pharma  AG  submitted  on  9  March  2006  an  application  for  Marketing 
Authorisation to the European Medicines Agency (EMEA) for Fesoterodine, through the centralised 
procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised 
procedure was agreed upon by the EMEA/CHMP on 16 December 2005.  
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Dr. Gonzalo Calvo Rojas 
Co-Rapporteur:  Dr. Tomas Salmonson 
1.2  Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 9 March 2006.  
The procedure started on 29 March 2006. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  22  June 
2006  (Annex  1).  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 13 June 2006 (Annex 2).  
During  the  meeting  on  24-27  July  2006,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on  27 July 2006 (Annex 3). 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  04 
October 2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on  14 November 2006 (Annex 4). 
During the CHMP meeting on 11-14 December 2006, the CHMP agreed on a list of outstanding 
issues to be addressed in writing by the applicant (Annex 5). 
The  applicant  submitted  the  responses  to  the  CHMP  list  of  outstanding  issues  on  17  January 
2007. 
The Rapporteurs circulated the Joint Response Assessment Report on the applicant’s responses 
to the List of Outstanding Issues to all CHMP members on 2 February 2007 (Annex 6). 
During  the  meeting  on  19-22  February  2007,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to TOVIAZ on 22 February 2007. The applicant provided 
the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  20 
February 2007 (Annex 7). 
©EMEA 2007 
1/1 
 
 
 
 
 
 
 
 
 
 
 
